MaxCyte has announced the launch of the CHANGE-seq-BE and ONE-seq-BE off-target nomination assays.
Available through MaxCyte’s SeQure service, these assays address a key gap in genome-editing characterisation by offering sensitive identification of off-target sites for adenine- and cytosine-base editors (ABEs and CBEs).
SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and to prioritise regions for confirmation assays.
CHANGE-seq-BE is a sensitive, unbiased biochemical off-target nomination method for base editors, and ONE-seq-BE is the only nomination assay for base editors that provides full visibility of population-specific genetic variants that may impact off-target activity.
By combining these two assays, MaxCyte is uniquely positioned as a single-source provider of orthogonal nomination assays for base editors.
Together with SeQure’s existing confirmation assays for quantitative measurement of off-target editing and detection of structural variation, therapeutic developers can confidently assess off-target risks in the relevant cell and tissue context.
This is especially important as developers work to align with evolving regulatory expectations — including recent FDA guidance on off-target editing and genome safety — with a growing emphasis on orthogonal assays, assay sensitivity and modality-appropriate methods.
Maher Masoud, President and CEO at MaxCyte, commented: “Base editors are creating new opportunities for therapeutic development, while also requiring safety assessment strategies that reflect their mechanisms of action."
"The addition of CHANGE-seq-BE and ONE-seq-BE to our SeQure services gives developers access to sensitive, orthogonal off-target assessment capabilities that can help them to understand and mitigate off-target risk, building stronger data packages for clinical development.”
